Tango Therapeutics (TNGX) Other Operating Expenses (2020 - 2026)
Tango Therapeutics' (TNGX) quarterly Other Operating Expenses came in at -$36.8 million in Q1 2026, up 5.9% year-on-year from -$34.7 million in Q1 2025, and up 5.9% quarter-over-quarter from -$39.1 million in Q1 2025.
Tango Therapeutics (TNGX) Other Operating Expenses (2020 - 2026) Analysis & Trends
Tango Therapeutics' Other Operating Expenses history runs 4 years deep, the most recent figure standing at -$36.8 million for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Tango Therapeutics | 3.82 Bn | 3.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.79 Mn |
| Mar 31, 2025 | -39.10 Mn |
| Dec 31, 2024 | 122.03 Mn |
| Sep 30, 2024 | -36.97 Mn |
| Dec 31, 2020 | 2.91 Mn |